(Reuters) - U.S. drugmaker Bristol-Myers Squibb Co (N:) said on Monday it would buy heart drugs developer MyoKardia Inc (O:) for about $13 billion (10 billion pounds).
Bristol Myers will pay $225 per share in cash, a 61.2% premium to MyoKardia's Friday closing price.